Key result
A light gradient boosting model predicted 30-day readmission among oncology patients with an AUROC of 0.711, comparable to the existing Epic model (AUROC 0.697).
Why the study?
Predicting 30-day readmission risk is paramount to improving care quality, requiring comparison of variables available at different inpatient encounter timepoints to identify targets to reduce avoidable readmissions.
Do machine learning models using early encounter data improve 30-day readmission prediction compared to the existing Epic model in oncology patients?
Cohort (n=2,460)
Do machine learning models using early encounter data improve 30-day readmission prediction compared to the existing Epic model in oncology patients?
Absolute Event Rate: 0.711% vs 0.697%
Machine learning models using data from the first 48 hours of admission can predict 30-day readmission in oncology patients with comparable or slightly better performance than the existing Epic model, identifying novel actionable risk factors.
ML models may aid early readmission stratification in oncology; hypothesis-generating and requires prospective validation before practice change.
PURPOSE: Predicting 30-day readmission risk is paramount to improving the quality of patient care. In this study, we compare sets of patient-, provider-, and community-level variables that are available at two different points of a patient's inpatient encounter (first 48 hours and the full encounter) to train readmission prediction models and identify possible targets for appropriate interventions that can potentially reduce avoidable readmissions. METHODS: Using electronic health record data from a retrospective cohort of 2,460 oncology patients and a comprehensive machine learning analysis pipeline, we trained and tested models predicting 30-day readmission on the basis of data available within the first 48 hours of admission and from the entire hospital encounter. RESULTS: Leveraging all features, the light gradient boosting model produced higher, but comparable performance (area under receiver operating characteristic curve [AUROC]: 0.711) with the Epic model (AUROC: 0.697). Given features in the first 48 hours, the random forest model produces higher AUROC (0.684) than the Epic model (AUROC: 0.676). Both models flagged patients with a similar distribution of race and sex; however, our light gradient boosting and random forest models were more inclusive, flagging more patients among younger age groups. The Epic models were more sensitive to identifying patients with an average lower zip income. Our 48-hour models were powered by novel features at various levels: patient (weight change over 365 days, depression symptoms, laboratory values, and cancer type), hospital (winter discharge and hospital admission type), and community (zip income and marital status of partner). CONCLUSION: We developed and validated models comparable with the existing Epic 30-day readmission models with several novel actionable insights that could create service interventions deployed by the case management or discharge planning teams that may decrease readmission rates over time.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2023) conducted a cohort in Oncology (n=2,460). Light gradient boosting and random forest models vs. Epic 30-day readmission model was evaluated on 30-day readmission prediction (AUROC). A light gradient boosting model predicted 30-day readmission among oncology patients with an AUROC of 0.711, comparable to the existing Epic model (AUROC 0.697).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: